CD47 promotes tumor invasion and metastasis in non-small cell lung cancer

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Zhao, Hui ^a   Wang, Jianxin ^a   Kong, Xiaodan ^a   Li, Encheng ^a   Liu, Yuanbin ^b   Du, Xiaohui ^a   Kang, Zhijie ^a   Tang, Ying ^a   Kuang, Yanbin ^a   Yang, Zhihui ^a   Zhou, Youwen ^c   Wang, Qi ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

^b WENZHOU MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CD47 ANTIGEN; CD47 PROTEIN, HUMAN;

A-549 CELL LINE; ANIMAL; BAGG ALBINO MOUSE; CELL LINE; DRUG SCREENING; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LUNG TUMOR; MALE; METABOLISM; METASTASIS; MIDDLE AGED; NON SMALL CELL LUNG CANCER; NUDE MOUSE; PATHOLOGY; PROCEDURES; RNA INTERFERENCE; RNAI THERAPEUTICS; TUMOR CELL LINE; TUMOR INVASION;

A549 CELLS; ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CD47 ANTIGEN; CELL LINE; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MALE; MICE, INBRED BALB C; MICE, NUDE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; RNA INTERFERENCE; RNAI THERAPEUTICS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84978643558     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep29719     Document Type: Article

References (43)

1. World Health Organization International Agency for Research on Cancer. GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. [Accessed February 19, 2015].
2. Morgensztern, D., Ng, S. H., Gao, F. & Govindan, R. Trends in stage distribution for patients with non-small cell lung cancer: a National Cancer Database survey. J ToracOncol 5, 29-33 (2010).
3. Carney, D. N. & Hansen, H. H. Non-small-cell lung cancer-stalemate or progress? N Engl J Med 343, 1261-1262 (2000).
4. Howlader, N. et al. SEER Cancer Statistics Review, 1975-2012; National Cancer Institute: Bethesda, MD, USA, (2015).
5. Baccelli, I. et al. Identifcation of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograf assay. Nat Biotechnol 31, 539-544 (2013).
6. Tsai, R. K. & Discher, D. E. Inhibition of "self "engulfment through deactivation of myosin-II at the phagocytic synapse between human cells, J Cell Biol 180, 989-1003 (2008).
7. Majeti, R. et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 138, 286-299 (2009).
8. Chao, M. P. et al. Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia. Cancer Res 71, 1374-1384 (2011).
9. Chao, M. P. et al. Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy. Blood 118, 4890-4901 (2011).
10. Kim, D. et al. Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells. Leukemia 26, 2538-2545 (2012).
11. Zhang, H. et al. HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells. Proc Natl AcadSci USA 112, E6215-E6223 (2015).
12. Steinert, G. et al. Immune escape and survival mechanisms in circulating tumor cells of colorectal cancer. Cancer Res 74, 1694-1704 (2014).
13. Lee, T. K. et al. Blockade of CD47-mediated cathepsin S/protease-activated receptor 2 signaling provides a therapeutic target for hepatocellular carcinoma. Hepatology 60, 179-191 (2014).
14. Wang, Y. et al. Intravenous delivery of siRNA targeting CD47 efectively inhibits melanoma tumor growth and lung metastasis. MolTer 21, 1919-1929 (2013).
15. Rodriguez, P. L. et al. Minimal "Self " peptides that inhibit phagocytic clearance and enhance delivery of nanoparticles. Science 339, 971-975 (2013).
16. Willingham, S. B. et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl AcadSci USA 109, 6662-6667 (2012).
17. Maes, H. et al. BNIP3 supports melanoma cell migration and vasculogenic mimicry by orchestrating the actin cytoskeleton. Cell Death Dis 5, e1127, doi: 10.1038/cddis.2014.94 (2014).
18. Miyashita, M. et al. Promotion of neurite and flopodium formation by CD47: roles of integrins, Rac, and Cdc42. MolBiol Cell 15, 3950-3963 (2004).
19. Aneta, G., Tomáš, V. , Daniel, R. & Jan, B. Cell polarity signaling in the plasticity of cancer cell invasiveness. Oncotarget, doi: 10.18632/oncotarget.7214 (Feb 8 2016).
20. Stengel, K. & Zheng, Y. Cdc42 in oncogenic transformation, invasion, and tumorigenesis. Cell Signal 23, 1415-1423 (2011).
21. Guo, Y. et al. R-Ketorolac Targets Cdc42 and Rac1 and Alters Ovarian Cancer Cell Behaviors Critical for Invasion and Metastasis. Mol Cancer Ter 14, 2215-2227 (2015).
22. Liu, Y. et al. Abnormal expression of p120-catenin, E-cadherin, and small GTPases is signifcantly associated with malignant phenotype of human lung cancer. Lung Cancer 63, 375-382 (2009).
23. Zuo, Z. et al. High mobility group Box-1 inhibits cancer cell motility and metastasis by suppressing activation of transcription factor CREB and nWASP expression. Oncotarget. 5, 7458-7470 (2014).
24. Zhao, X. W. et al. CD47-signal regulatory protein-a (SIRPa) interactions form a barrier for antibody- mediated tumor cell destruction. Proc Natl Acad Sci USA 108, 18342-18347 (2011).
25. Xiao, Z. et al. Antibody mediated therapy targeting CD47 inhibits tumor progression of hepatocellular carcinoma. Cancer Lett 360, 302-309 (2015).
26. Ciof, M. et al. Inhibition of CD47 Efectively Targets Pancreatic Cancer Stem Cells via Dual Mechanisms. Clin Cancer Res 21, 2325-2337 (2015).
27. Baccelli, I. et al. Co-expression of MET and CD47 is a novel prognosticator for survival of luminal breast cancer patients. Oncotarget 5, 8147-8160 (2014).
28. Chao, M. P., Weissman, I. L. & Majeti, R. The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications. CurrOpinImmunol 24, 225-232 (2012).
29. Xu, J. F. et al. CD47 blockade inhibits tumor progression human osteosarcoma in xenografmodels. Oncotarget 6, 23662-23670 (2015).
30. Chung, S., Sudo, R., Vickerman, V. , Zervantonakis, I. K. & Kamm, R. D. Microfuidic platforms for studies of angiogenesis, cell migration, and cell-cell interactions. Sixth International Bio-Fluid Mechanics Symposium and Workshop March 28-30, 2008 Pasadena, California. Ann Biomed Eng 38, 1164-1177 (2010).
31. Jeon, J. S. et al. Human 3D vascularized organotypic microfuidic assays to study breast cancer cell extravasation. Proc Natl AcadSci USA 112, 214-219 (2015).
32. Bersini, S. et al. A microfuidic 3D in vitro model for specifcity of breast cancer metastasis to bone. Biomaterials 35, 2454-2461 (2014).
33. Zervantonakis, I. K. et al. Tree-dimensional microfuidic model for tumor cell intravasation and endothelial barrier function. Proc Natl AcadSci USA 109, 13515-13520 (2012).
34. Jeon, J. S. et al. Generation of 3D functional microvascular networks with mural cell-diferentiated human mesenchymal stem cells in microfuidic vasculogenesis systems. IntegrBiol (Camb) 6, 555-563 (2014).
35. Edris, B. et al. Antibody therapy targeting the CD47 protein is efective in a model of aggressive metastatic leiomyosarcoma. Proc Natl AcadSci USA 109, 6656-6661 (2012).
36. Barclay, A. N. & Van Den Berg, T. K. The Interaction between Signal Regulatory Protein Alpha (SIRPα ) and CD47: Structure, Function, and Terapeutic Target. Annu Rev Immunol 32, 25-50 (2014).
37. Tucci, M. G. et al. Involvement of E- cadherin, beta-catenin, Cdc42 and CXCR4 in the progression and prognosis of cutaneous melanoma. The British journal of dermatology 157, 1212-1216 (2007).
38. Reymond, N. et al. Cdc42 promotes transendothelial migration of cancer cells through beta1 integrin. J Cell Biol 199, 653-668 (2012).
39. Sick, E. et al. CD47 update: a multifaceted actor in the tumour microenvironment of potential therapeutic interest. Br J Pharmacol. 167, 1415-1430 (2012).
40. Bialkowska, K., Zafran, Y. , Meyer, S. C. & Fox, J. E. 14-3-3 zeta mediates integrin-induced activation of Cdc42 and Rac. Platelet glycoprotein Ib-IX regulates integrin-induced signaling by sequestering 14-3-3 zeta. J Biol Chem. 278, 33342-33350 (2003).
41. Dermot, C., Marian, B. & Niamh, M. Integrins as therapeutic targets: lessons and opportunities. Nature Reviews Drug Discovery. 9, 804-820 (2010).
42. Fischer, K. R. et al. Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature 527, 472-476 (2015).
43. Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25, 402-408 (2001).